鲜有药企能像科伦博泰一样,以惊人的速度持续突破自我。过去一年,它如同一匹疾驰的骏马,在创新研发、商业化和全球化多赛道中全力冲刺——TROP2 ADC(佳泰莱®)夺得肺癌领域全球首个获批,并惊艳亮相ASCO、ESMO、NEJM等国际顶级学术舞台;HER2 ADC(舒泰莱®)疗效超越T-DM1,进一步丰富HER2+乳腺癌治疗选择;多个创新项目高速推进,以更快节奏进入临床与市场;灵活的双向BD落地,搭建...
Source Link鲜有药企能像科伦博泰一样,以惊人的速度持续突破自我。过去一年,它如同一匹疾驰的骏马,在创新研发、商业化和全球化多赛道中全力冲刺——TROP2 ADC(佳泰莱®)夺得肺癌领域全球首个获批,并惊艳亮相ASCO、ESMO、NEJM等国际顶级学术舞台;HER2 ADC(舒泰莱®)疗效超越T-DM1,进一步丰富HER2+乳腺癌治疗选择;多个创新项目高速推进,以更快节奏进入临床与市场;灵活的双向BD落地,搭建...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.